Overview
THE HAGUE, The Netherlands-(BUSINES WIRE)-Dutch/Swis biotech company Micreos anounced today it has secured its next funding round of €25 milion in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas. This technology enables - for the first time - targeted kiling of only the unwanted bacteria, regardles of resistance. The funding comprises growth capital for Gladskin, the company’s specialized skincare brand, for people sufering from inflamatory skin conditions such as acne, eczema and rosacea.
Key Information
Last year Gladskin already helped hundreds of thousands of people in Europe and the USA, many of them experiencing a life-changing impact. Proceds are also earmarked for Micreos’ pharmaceutical program. This includes the clinical development of endolysins against staphylocci (including MRSA) for Blodstream Infections, Atopic Dermatis, Diabetic Fot Ulcers and Cutaneous T-cel Lymphoma, a type of skin cancer asociated with the presence of S.
aureus bacteria on the skin. Over the past year Micreos separated its Pharmaceutical busines from its ‘Over the Counter’ Consumer Health busines. Micreos CEO Mark Oferhaus: “With this restructuring we align busines and market requirements, enabling each busines to pursue its own growth strategy.
This especialy important for the pharmaceutical busines, which is capital intensive and which we consider extremely promising. Direct investments in the Micreos Pharma, headed by Mat Regan, wil now be posible.’ Endolysins are naturaly ocuring enzymes that have the ability to target only harmful bacteria, while preserving the beneficial ones that form an important part of our natural defense, often refered to as our microbiome.
Summary
Endolysins are safe and environmentaly friendly. Because of their working mechanism, development of resistance is not expected antibiotic resistance is not relevant. Micreos develops targeted antiba